Do statins have a role in the management of diastolic dysfunction?

American Journal of Cardiovascular Drugs

Volumn 8, Issue 5, 2008, Pages 297-303

  Biria, Mazda ^a   Howard, Patricia A ^a   Vacek, James ^a  

^a UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

Cardiovascular disorders, treatment; HMG CoA reductase inhibitors, pharmacodynamics; HMG CoA reductase inhibitors, therapeutic use

Indexed keywords

CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CYTOKINE PRODUCTION; DIASTOLIC DYSFUNCTION; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOM;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIASTOLE; DISEASE PROGRESSION; HEART FAILURE, DIASTOLIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 54749102333     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808050-00002     Document Type: Review

References (92)

1. Kwan ML, Habel LA, Flick ED, et al. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 2008 Jun; 109 (3): 573-9
2. Khurana V, Bejjanki HR, Caldito G, et al. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007 May; 131 (5): 1282-8
3. Ishida W, Kajiwara T, Ishii M, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 2007 Jul; 212 (3): 265-73
4. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007 May; 292 (5): L1105-10
5. Chua D, Tsang RS, Kuo IF. The role of statin therapy in sepsis. Ann Pharmacother 2007 Apr; 41 (4): 647-52
6. Kanda H, Yokota K, Kohno C, et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol 2007; 17 (5): 364-8
7. Bauersachs J, Hiss K, Fraccarollo D, et al. Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by antiinflammatory effects. Cardiovasc Res 2006 Dec 1; 72 (3): 438-46
8. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? Am Heart J 2006 Jul; 152 (1): 39-49
9. Palmieri V, Russo C, Palmieri EA, et al. Isolated left ventricular diastolic dysfunction: implications for exercise left ventricular performance in patients without congestive heart failure. J Am Soc Echocardiogr 2006 May; 19 (5): 491-8
10. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387-93
11. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II. Causal mechanisms and treatment. Circulation 2002 Mar 26; 105 (12): 1503-8
12. Arias MA, Sanchez-Gila J. Statins and diastolic heart failure. Int J Cardiol 2007 Jan 31; 115 (1): 91-2
13. Zile MR. Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. Circulation 2005 Jul 19; 112 (3): 300-3
14. Chen Y, Ohmori K, Mizukawa M, et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007 Jan; 71 (1): 144-52
15. Entok E, Unalir A, Cavusoglu Y, et al. Long-term effects of antilipidaemic therapy on left ventricular function in patients with dyslipidaemia: multigated radionuclide ventriculography study. Nucl Med Commun 2005 Sep; 26 (9): 773-9
16. Fukuta H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005 Jul 19; 112 (3): 357-63
17. Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004 Nov 15; 94 (10): 1306-10
18. Okura H, Asawa K, Kubo T, et al. Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure. Intern Med 2007; 46 (17): 1337-43
19. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976 Dec 31; 72 (2): 323-6
20. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997 Sep 15; 11 (18): 2295-322
21. Moon SY, Zheng Y. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol 2003 Jan; 13 (1): 13-22
22. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000 Jul 14; 67 (8): 863-76
23. Inoue I, Itoh F, Aoyagi S, et al. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002 Jan 11; 290 (1): 131-9
24. Roglans N, Sanguino E, Peris C, et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 2002 Jul; 302 (1): 232-9
25. Ortego M, Bustos C, Hernández-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999 Dec; 147 (2): 253-61
26. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998 Oct; 32 (4): 865-75
27. Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202
28. Little CW. Assessment of normal and abnormal cardiac function. In: Braunwald E, Zipes D, Libby P, editors. Heart disease: a textbook of cardiovascular medicine. 6th ed. Orlando (FL): WB Saunders Company, 2001: 479-500
29. Alpert NR, LeWinter M, Mulieri LA, et al. Chemomechanical energy transduction in the failing heart. Heart Failure Rev 1999 Oct; 4 (3): 1382-4147
30. Krämer BK, Smith TW, Kelly RA. Endothelin and increased contractility in adult rat ventricular myocytes: role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger. Circ Res 1991 Jan; 68 (1): 269-79
31. 2+ transients and contractility in rabbit ventricular myocardium. Life Sci 1998; 62 (17-18): 1485-9
32. Apstein CS, Gravino FN, Haudenschild CC. Determinants of a protective effect of glucose and insulin on the ischemic myocardium: effects on contractile function, diastolic compliance, metabolism, and ultrastructure during ischemia and reperfusion. Circ Res 1983 May; 52 (5): 515-26
33. Varma N, Morgan JP, Apstein CS. Mechanisms underlying ischemic diastolic dysfunction: relation between rigor, calcium homeostasis, and relaxation rate. Am J Physiol Heart Circ Physiol 2003 Mar; 284 (3): H758-71
34. Zheng X, Hu SJ. Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacol Sin 2005 Jun; 26 (6): 696-704
35. Saka M, Obata K, Ichihara S, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006 Jun; 47 (6): 770-9
36. Jguirim-Souissi I, Jelassi A, Addad F, et al. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease. Am J Cardiol 2007 Jul 1; 100 (1): 23-7
37. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 2006 Oct; 291 (4): H1738-45
38. Riessen R, Axel DI, Fenchel M, et al. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res Cardiol 1999 Oct; 94 (5): 322-32
39. Graf K, Kappert K, Stawowy P, et al. Statins regulate alpha2beta1-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells. J Cardiovasc Pharmacol 2003 Jan; 41 (1): 89-96
40. Jones SP, Teshima Y, Akao M, et al. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 2003 Oct 17; 93 (8): 697-9
41. Lee TM, Lin MS, Tsai CH, et al. Effects of pravastatin on ventricular remodeling by activation of myocardial KATP channels in infarcted rats: role of 70-kDa S6 kinase. Basic Res Cardiol 2007 Mar; 102 (2): 171-82
42. Lee TM, Chou TF, Tsai CH. Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. J Mol Cell Cardiol 2003 Dec; 35 (12): 1449-59
43. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006 Jan 17; 47 (2): 332-7
44. Ozkiris A, Erkilic K, Koc A, et al. Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy. Br J Ophthalmol 2007 Jan; 91 (1): 69-73
45. Nemes A, Neu K, Forster T, et al. Relationship between hypercholesterolemia, lipid-lowering therapy and coronary flow velocity reserve evaluated by stress transesophageal echocardiography in patients with a negative coronary angiogram. Echocardiography 2004 Jan; 21 (1): 37-41
46. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003 Jan; 83 (1): 59-115
47. Farhangkhoee H, Khan ZA, Kaur H, et al. Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. Pharmacol Ther 2006 Aug; 111 (2): 384-99
48. Rydén L, Standl E, Bartnik M, et al., on behalf of the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC), European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 Jan; 28 (1): 88-136
49. Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005 Jul 5; 112 (1): 93-102
50. Schmeer C, Kretz A, Isenmann S. Therapeutic potential of 3-hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases. CNS Neurol Disord Drug Targets 2007 Aug; 6 (4): 282-7
51. Yamagishi S, Nakamura K, Matsui T, et al. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med Hypotheses 2006; 66 (5): 1019-21
52. Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci U S A 2002 Jun 11; 99 (12): 8301-5
53. Ota T, Takamura T, Ando H, et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003 Jun; 46 (6): 843-51
54. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000 Nov; 30 (11): 980-7
55. Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007 Apr; 49 (4): 792-8
56. Minami M, Atarashi K, Ishiyama A, et al. Effects of cholesterol-lowering therapy on pressor hyperreactivity to stress in hypercholesterolemic patients. Hypertens Res 2003 Apr; 26 (4): 273-80
57. Tonstad S, Furu K, Rosvold EO, et al. Determinants of control of high blood pressure: the Oslo Health Study 2000-2001. Blood Press 2004; 13 (6): 343-9
58. Terzoli L, Mircoli L, Raco R, et al. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005 Sep; 46 (3): 310-5
59. Tonelli M, Sacks F, Pfeffer M, et al. Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens 2006 Aug; 20 (8): 560-5
60. Borghi C, Dormi A, Veronesi M, et al., for the Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004 Aug; 148 (2): 285-92
61. Leibovitz E, Hazanov N, Zimlichman R, et al. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001 Nov; 14 (11 Pt 1): 1096-8
62. Kanbay M, Yildirir A, Bozbas H, et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail 2005; 27 (3): 297-303
63. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000 Apr; 35 (4): 549-55
64. Danaoglu Z, Kultursay H, Kayikcioglu M, et al. Effect of statin therapy added to ACE-inhibitors on blood pressure control and endothelial functions in normolipidemic hypertensive patients. Anadolu Kardiyol Derg 2003 Dec; 3 (4): 331-7
65. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002 Mar 20; 39 (6): 1020-5
66. Zanchetti A, Crepaldi G, Bond MG, et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study: PHYLLIS study group. J Hypertens 2001 Jan; 19 (1): 79-88
67. Dilaveris P, Giannopoulos G, Riga M, et al. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007 Jul; 5 (3): 227-37
68. Verreth W, De Keyzer D, Davey PC, et al. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br J Pharmacol 2007 Jun; 151 (3): 347-55
69. Monetti M, Canavesi M, Camera M, et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res 2007 May; 55 (5): 441-9
70. Abhayaratna WP, Barnes ME, O'Rourke MF, et al. Relation of arterial stiffness to left ventricular diastolic function and cardiovascular risk prediction in patients > or = 65 years of age. Am J Cardiol 2006 Nov 15; 98 (10): 1387-92
71. Yambe M, Tomiyama H, Hirayama Y, et al. Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res 2004 Sep; 27 (9): 625-31
72. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001 Apr; 37 (5): 1351-8
73. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998 Jul 21; 98 (3): 211-6
74. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998 Jun 15; 101 (12): 2711-9
75. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001 Jan 16; 103 (2): 276-83
76. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001 Feb 20; 103 (7): 926-33
77. Kang L, Fang Q, Hu SJ. Regulation of phospholamban and sarcoplasmic reticulum Ca2+-ATPase by atorvastatin: implication for cardiac hypertrophy. Arch Pharm Res 2007 May; 30 (5): 596-602
78. Saka M, Obata K, Ichihara S, et al. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. Clin Exp Pharmacol Physiol 2006 Dec; 33 (12): 1164-71
79. Senthil V, Chen SN, Tsybouleva N, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2005 Aug 5; 97 (3): 285-92
80. Rasburg S, Pras M, Lidar M, et al. Extremely high dose pravastatin may suppress amyloidogenesis in a mouse model. Ann Rheum Dis 2002 Jun; 61 (6): 572
81. Petanceska SS, DeRosa S, Sharma A, et al. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci 2003; 20 (3): 395-406
82. Kiechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997 Nov 18; 96 (10): 3300-7
83. Iribarren C, Sempos CT, Eckfeldt JH, et al. Lack of association between ferritin level and measures of LDL oxidation: the ARIC study. Atherosclerosis risk in communities. Atherosclerosis 1998 Jul; 139 (1): 189-95
84. de Sotomayor MA, Perez-Guerrero C, Herrrera MD, et al. Improvement of age-related endothelial dysfunction by simvastatin: effect on NO and COX pathways. Br J Pharmacol 2005 Dec; 146 (8): 1130-8
85. Brouilette SW, Moore JS, McMahon AD, et al., West of Scotland Coronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007 Jan 13; 369 (9556): 107-14
86. Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol 2007 Jan; 46 (1): 1-9
87. Jasińska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007 Sep-Oct; 59 (5): 483-99
88. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004 Apr 6; 109 (13): 1594-602
89. Kiliszek M, Burzyńska B, Styczyński G, et al. A1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatment. Clin Chem Lab Med 2007; 45 (7): 839-42
90. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004 Nov 9; 110 (19): 3136-42
91. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003 May 16; 92 (9): 1049-55
92. Haendeler J, Hoffmann J, Diehl JF, et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 2004 Apr 2; 94 (6): 768-75